Abstract Latent Transforming Growth Factor beta (TGFβ) Binding Proteins (LTBPs) are chaperones and determinants of TGFβ isoform-specific secretion. They belong to the LTBP/Fibrillin family and form integral components of the fibronectin and microfibrillar extracellular matrix (ECM). LTBPs serve as master regulators of TGFβ bioavailability, functioning to incorporate and spatially pattern latent TGFβ at regular intervals within the ECM, and actively participate in integrin-mediated stretch activation of TGFβ in vivo. In so doing they create a highly patterned sensory system where local changes in ECM tension can be detected and transduced into focal signals. The physiological role of LTBPs in the mammary gland remains largely unstudied, however both loss and gain of LTBP expression is found in breast cancers and breast cancer cell lines. Importantly, elevated LTBP1 levels appear in two gene signatures predictive of enhanced metastatic behavior. LTBP may promote metastasis by providing the bridge between structural and signaling components of the epithelial to mesenchymal transition (EMT).
Introduction
TGFβs are small peptides (25 kDa dimer) belonging to a superfamily of over thirty related disulphide-linked dimeric growth factors that includes the bone morphogenetic proteins (BMPs), inhibins and activins, and growth and differentiation factors (GDFs). TGFβs are multifunctional: they inhibit proliferation, enhance ECM synthesis, promote apoptosis, downregulate cell-cell and upregulate cell-matrix adhesion receptor expression to favor cell movement, and regulate diverse immune responses. All three mammalian TGFβ isoforms (TGFβ1-3) are produced in dynamic temporal-spatial expression patterns during mammary development and the mammary cycle [1] [2] [3] [4] . TGFβ signaling within the mammary stroma inhibits HGF and induces Wnt5a expression, which acts in a paracrine fashion to attenuate ductal morphogenesis during puberty [5, 6] . Luminal TGFβ signaling prevents precocious alveolar production and differentiation in virgin mice and TGFβ1 suppresses proliferation of ductal ERpositive cells in an autocrine manner [1, 3, 7, 8] . Physiological upregulation of TGFβ3 expression promotes alveolar apoptosis during involution [9] . In keeping with the above roles, gain of TGFβ signaling results in ductal hypoplasia and compromised alveologenesis, whereas loss or suppression of signaling leads to precocious ductal extension and alveologenesis, hyperbranching and delayed involution depending on the specific cell-type targeted [10] [11] [12] [13] . Importantly, TGFβ exerts biphasic effects in breast cancer. By maintaining cells in a quiescent state during normal homeostasis TGFβ functions as a breast tumor suppressor. However, during malignant progression, as cells lose or block the TGFβ growth inhibition pathway, alternative TGFβ signaling routes can induce epithelial to mesenchymal transition (EMT) and, as a consequence, promote metastatic dissemination and acquisition of stem cell properties [14, 15] . In addition to its role in breast cancer, TGFβ signaling also contributes significantly to the development of radiationinduced breast fibrosis [16] .
A key feature that distinguishes TGFβ1-3 from most other members of the TGFβ superfamily, and which is central to understanding their biology, is their secretion in a latent form [17, 18] . All three TGFβs are widely expressed and act though a common receptor system that is found on most cells to trigger intracellular signal transduction [14, 17] . Thus specificity of TGFβ action lies not in transcriptional regulation of ligand or receptor expression but is instead determined by three key posttranscriptional events: 1) regulation of latent TGFβ secretion, 2) spatial targeting, localization and deposition of latent TGFβ within the ECM and 3) subsequent temporal activation, involving release or steric exposure of the mature TGFβ ligand from its latent complex [18] . Latent TGFβ binding proteins (LTBPs) play critical roles in each of these three events and thus are master regulators of the specific focal presentation of TGFβ to its receptors and render the matrix poised for conversation with overlying cells.
LTBPs: Essential TGFβ Chaperones and Determinants of TGFβ Isoform-Specific Secretion
LTBP1, as its name suggests, was discovered as a large molecular weight protein (125-160 kDa) covalently complexed to latent TGFβ [19] . This association forms within the biosynthetic compartment creating what is referred to as the large latent complex (LLC) (see Fig. 1 ) [20] . LTBP1 is synthesized in molar excess of pro-TGFβ and forms disulphide bonds with cysteine 33 in the TGFβ1 propeptide domain while in the endoplasmic reticulum [21, 22] . Here, TGFβ also dimerizes via three disulphide bonds: two between the propeptides and one between the TGFβ domains [19, 20, 23] . Once in the Golgi apparatus, TGFβ propeptides become glycosylated and are cleaved by furin but remain tightly associated with the mature TGFβ dimer (25 KDa) to sterically hinder and regulate subsequent interaction with its receptor. Hence, the cleaved TGFβ propeptide dimer is referred to by its functional property as the latency associated peptide (LAP). Importantly, in the absence of LTBP, LAP forms aberrant disulphide bonds within TGFβ, resulting in delayed secretion of a misfolded, denatured and inactivatable form of the latent complex [24] [25] [26] . Thus, the initial function of LTBP1 is that of a chaperone, which ensures correct folding and efficient secretion of latent TGFβ [20, 24] .
LTBPs coevolved with the TGFβ family and appear to have emerged in sea urchins [27] . Cloning and analysis of the human databases has revealed the presence of four genes, LTBP1-4, encoding a family of closely related proteins [28] [29] [30] [31] [32] . Genbank analyses also reveal the presence of pseudogenes for human LTBP1 and 3 and mouse Ltbp1, 2 and 4. LTBP2 and LTBP3 are transcribed from single promoters, whereas long and short isoforms of LTBP1 and LTBP4 are generated by transcription from two independent promoters. Extensive alternative splicing has been reported for all LTBPs, resulting in the expression of multiple tissuespecific variants with altered binding properties for TGFβ and/or ECM proteins (see Fig. 2 ) [2, 27] . All four LTBP mRNAs are produced in mouse mammary gland (Pinderhughes and Cowin unpublished results) and database analyses reveal that they are also expressed to varying degrees in human breast tissues and normal as well as breast cancer cell lines (see Table 1 ). LTBP1-4 differ in their binding affinities for specific TGFβ-LAP domains (see Table 2 ) [21, 22, 33, 34] . LTBP1 and 3 covalently bind to all three TGFβ-LAPs, whereas LTBP4 associates specifically with TGFβ1-LAP [33] . In contrast, LTBP2 is incapable of binding TGFβ-LAP and thus has no effect on TGFβ secretion. Differences in LTBP1, 3 and 4 expression patterns and TGFβ preferences, can therefore regulate not only the folding and rate of secretion but also influence which particular TGFβ species emerges from the cell.
The LTBP/Fibrillin Family: Integral Components of the ECM that Spatially Pattern Latent TGFβ
The role of LTBPs in TGFβ biology does not end at the cell surface. LTBPs remain bound to secreted latent TGFβ and play an essential role in determining the spatial pattern of latent TGFβ deposition within the ECM (see Fig. 1 ). LTBPs associate with at least two elements-fibronectin and microfibrils-and themselves form integral components of the ECM [35] [36] [37] . LTBPs show extensive sequence similarity with fibrillins, which form the major component of microfibrils that ensheath elastic fibers [27, [38] [39] [40] . LTBPs and fibrillins are organized into an N-terminal region, a hinge and a C-terminal rod that is stiffened by Ca 2+ association with multiple EGF-like repeats (see Fig. 2 ). Fibrillins are larger and in general contain twice as many EGF-like and 8-cysteine containing repeats (8-cys) as found in LTBPs. 8-cys repeats are found exclusively in LTBPs and fibrillins forming a hallmark of this family [27] . These structural domains come in two forms. One 8-cys repeat in LTBP1, 3 and 4 is structurally modified by a two-amino acid insertion that facilitates disulphide bond formation with LAP C33. All other 8-cys domains lack this modification [22, 33] . Thus LTBP1, 3 and 4 bind to LAP-TGFβ whereas LTBP2 and fibrillins fail to do so [21, 22, 33, 34] .
Upon exiting the cell, fibrillins initially associate with fibronectin and require this protein for further assembly. They copolymerize in a head to tail fashion, associate laterally in a staggered manner and become crosslinked to form microfibrils. Microfibrils have a~10 nm diameter 'beads-on-a-string' appearance and provide a scaffold for incorporation of elastin and numerous other components which assemble to form elastic fibers [38, [41] [42] [43] . In Figure 1 Assembly and function of latent-TGFβ. a The tripartite large latent complex (LLC) is formed early in the rough endoplasmic reticulum (RER), via disulphide bonding first between two TGFβ proprotein monomers to form pro-TGFβ, and then between pro-TGFβ and the 8-cys domain of LTBP. In the Golgi, furin mediates the cleavage of pro-TGFβ into dimeric TGFβ and its propeptide, latency associated protein (LAP). These two homodimers associate noncovalently to form the small latent complex (SLC). LTBP acts as a chaperone, ensuring proper folding and disulphide bonding between LAP and TGFβ. LAP is also glycosylated in the Golgi at mannose-6-phosphate groups, which may be important in extracellular signaling.
The mature LLC is then secreted. b The LLC positions itself within the extracellular matrix (ECM) first by LTBP binding through its N-terminus (N) to fibronectin and later through its C-terminus (C) binding to N-terminus of fibrillin in microfibrils. This maintains extracellular TGFβ in its latent state. c Latent TGFβ is activated via integrins in the stretch mechanism. Upon mechanical signal from the actin cytoskeleton, integrins bind to RGD sites on LAP. As LTBP maintains its hold on the ECM during this process, the two opposing forces allow a conformational change in LAP that releases TGFβ from the complex, activating it and allowing it to bind its receptor, TGF-βR addition to providing docking sites for LTBPs, fibrillins also capture other TGFβ superfamily members, such as BMPs, and thus are viewed as multifaceted signaling platforms within the ECM [43] .
LTBPs initially associate with fibronectin through specific sequences in their N-terminal region [36, 37] . Fibronectin is required for LTBP incorporation into ECM and this association is promoted by transglutaminase [37, [44] [45] [46] . At later stages LTBPs colocalize with microfibrils through specific interactions between the LTBP C-terminal domain and the fibrillin-1 N-terminus [35, 47] . Thus, LTBP is a structural element of both the fibronectin ECM and microfibril-associated complexes and theoretically can bridge these two ECM components via independent N-and C-terminal interactions (see Fig. 1 ). However, it has been proposed that fibronectin provides a template or guide for LTBP1 and 4 deposition and subsequent transfer to microfibrils [43] . Regardless, through these two types of interaction LTBPs incorporate and sequester silos of latent TGFβ poised for activation at regular coordinates within the ECM. In so doing they create a highly patterned sensory system where local changes in ECM tension can be detected and transduced into focal signals. Of note, among other responses, TGFβ signals elicit further matrix and integrin production. Thus, LTBP creates a mechano-sensory net that spatially senses and generates a highly localized feedback response to the physical tractile requirements of the cellular microenvironment.
An important facet of LTBP biology in this regard is that LTBP binding to the matrix occurs independently of its ability to interact with TGFβ. A corollary of this is that factors that increase LTBP expression in excess of TGFβ, or factors that regulate expression of isoforms that are unable to interact with TGFβ, will theoretically induce a dominant negative effect on TGFβ bioavailability. LTBP1 and 4 are both synthesized in excess of proTGFβ, whereas LTBP3 and TGFβ expression and secretion are tightly coregulated [48] . LTBP2 and some variants of other LTBPs cannot associate with TGFβ but compete with LTBP1 for the same sites on fibrillins and thus might competitively reduce latent TGFβ incorporation into the ECM. Additional proteins, for example fibulins 2, 4 and 5, also compete with LTBP1 for fibrillin association [38] .
LTBPs Play a Significant Role in the Physiological and Pathological Activation of TGFβ In Vivo
In vitro studies have identified a number of factors that can liberate TGFβ from latent complexes. Denaturing conditions, for example, heat, acid, chaotropic agents and 
detergents all activate TGFβ and TGFβ is also activated by irradiation and reactive oxygen species [49] [50] [51] [52] . Activation by plasmin has been described in co-cultures of smooth muscle and endothelial cells, with steps involving localization of the LLC to the ECM, release by proteolytic cleavage, binding of sugar moieties in LAP to mannose-6-phosphate receptors on the cell surface and liberation of TGFβ by plasmin cleavage of LAP [53] . In this type of activation, LTBPs are perceived as functioning to concentrate latent TGFβ on the ECM and/or the cell surface [44, 54] . Although platelet derived TGFβ becomes activated when blood clots are dissolved with plasmin, the general physiological relevance of this mechanism has been called into question by the finding that plasminogen null mice do not phenocopy TGFβ null mice [55] . However, plasmin may act redundantly with other proteolytic mechanisms [43, 56] . Finally, thrombospondin 1 has been shown to bind simultaneously to LAP and TGFβ, altering their affinity for one another [57] . Thrombospondin 1 null mice phenocopy some aspects of TGFβ null mice supporting the relevance of this mechanism in vivo [58, 59] .
A series of studies have provided strong evidence for the physiological importance of integrin-mediated activation of TGFβ [60, 61] . LAP1 and 3 contain an integrin-binding RGD sequence that in LAP1 bind integrins αvβ1, αvβ3, αvβ5 αvβ6 and αvβ8, as well as α8β1 and in LAP3 bind αvβ6 and αvβ8 [60] [61] [62] [63] [64] [65] [66] . Integrins αvβ3, αvβ5 and αvβ6, αvβ8, activate TGFβ signaling in vitro [61, 64, [67] [68] [69] [70] . The physiological relevance of αvβ6 and αvβ8 integrinmediated TGFβ activation in vivo is strongly supported by the fact that αv, β6 and β8 integrin null mice phenocopy aspects of TGFβ1 and TGFβ3 null mice [60, 65, [71] [72] [73] [74] [75] [76] [77] . For example, both TGFβ null and integrin β6 null mice show lung and skin inflammation and are resistant to bleomycin-induced fibrosis, a pathology that is associated with excess TGFβ signaling [65] . Finally, knock-in mice homozygous for the LAP1 RGE/RGE allele completely recapitulate the TGFβ1 null phenotype [78] . Thus integrin binding is essential for TGFβ signaling during development and in fibrosis.
Two distinct integrin-mediated roles in TGFβ activation have been proposed. In one model, integrin αvβ8 is proposed to recruit the cell surface protease, MT1-MMP, into close proximity with LAP, facilitating LAP cleavage and liberating TGFβ [63, 79] . Of note, in the integrinprotease recruitment model LTBPs are relegated to a passive role in presenting latent TGFβ as a substrate. A second model proposes a more active participatory role for LTBPs (see Fig. 1c) . Here, the binding of integrins to the RGD sequence in LAP, which, in turn, is bound to LTBP, is proposed to create a bridge between the actin cytoskeleton and the ECM (see Fig. 1c ) [65, 67] . As a consequence, traction generated by actin stress fibers within or by tensile force outside of the cell contorts LAP and exposes TGFβ to its receptor. To date three integrins, αvβ3, αvβ5, and αvβ6 have been shown to activate TGFβ independently of proteases [65, 67, 68] . Myoepithelial cells in the mammary gland express α1, α5 and αv and both myoepithelial and luminal cells express α2, α3, α6, β1 and β4. Significantly, cultured mammary cells express αvβ3 and αvβ5 [80] . In vitro experiments have shown that integrin-dependent but protease-independent TGFβ signaling requires 1) an intact integrin C-terminal binding domain for cytoskeletal binding partners and is abrogated by agents that disrupt actin in polymerization or block myofibroblast contraction, 2) a mechanically stiff matrix that allows force generation [61, 65, 67, 68] . Several lines of evidence support the critical involvement of LTBPs in stretch-induced signaling: a requirement for the LTBP bridge has been suggested by experiments indicating that TGFβ signaling is promoted by stretching myofibroblasts and demonstrated directly by showing that deletion of the LTBP1 ECM-binding hinge domain abrogates signaling, and expression of a recombinantly engineered minimal LTBP1 ECM-binding hinge domain coupled to the LAP binding domain is sufficient to support TGFβ activation and signaling [67, 68] . Recent studies have shown that mice homozygous for a knock-in mutant allele of TGFβ1 harboring a mutation in C33S of LAP1 (TGFβ1 C33S/C33S) , which abrogates its association with LTBP, recapitulate key aspects of the TGFβ1 null phenotype. These mice display multi-organ inflammation, lack of skin Langerhans cells, and tumors of the stomach, rectum and anus [81] . Collectively, these data establish that LTBP1 is required for, and positively regulates, TGFβ1 and 3 signaling in many tissues in vivo. As LAP2 lacks the RGD sequence motif necessary for integrin association, TGFβ2 activation must involve other mechanisms [60] . Intriguingly, LTBP1 and 2 and all fibrillins also contain RGD sequences (see Fig. 2 ). Integrins α5β1, αvβ3 and αvβ6 bind to fibrillin 1, however to date, association between integrins and LTBPs has not been reported and the RGD sequences in LTBPs are not conserved across species [60, [82] [83] [84] [85] [86] [87] .
LTBPs are Required for and Regulate TGFβ Signaling
The importance of the precise ECM incorporation and patterning of TGFβ can best be appreciated in the phenotypes of knock-out mice and in human pathologies arising from mutations that disrupt LTBP/fibrillin multiprotein assemblies (see Table 3 ) [88] [89] [90] . Individual LTBP isoform-specfic knock-out mice show distinct phenotypes (see Table 4 ). Loss of LTBP1L results in embryonic and early postnatal lethality due to malformation of the major heart vessels and valves [91, 92] . LTBP3 knock-outs show craniofacial abnormalities, osteosclerosis and osteoarthritis and lung alveolar septation defects [93, 94] . LTBP4 hypomorphs present with severe pulmonary emphysema, secondary cardiomyopathy and are predisposed to colonic prolapse and colorectal cancer [95] . These mice show disruption of the elastic fibers [95] . Each of these mutants show evidence of loss of specific TGFβ deposition and signaling activity. However, further studies on LTBP4 null mice have suggested that the lung developmental defects arise from excessive TGFβ signaling and can be corrected by administering TGFβ antagonists or genetically reducing expression of TGFβ2 [96] . In contrast, their elastic fiber defects cannot be corrected and appear to result from TGFβ-independent functions of LTBP4 as a microfibrilassociated component and facilitator of elastic fiber formation [96] . Collectively, these studies indicate that Table 4 ) [60] . All LTBPs likely have additional TGFβ-independent functions. This is certainly true for LTBP2, which is unable to interact with TGFβ. LTBP2 nulls show early embryonic lethality due to implantation failure. LTBP2 has been proposed to regulates elastogenesis by targeting of fibulin-5 to microfibrils [97, 98] . In humans, LTBP2 mutations are associated with glaucoma and defects in lens development (see Table 3 ) [90] . Mutations in fibrillin have been linked to several genetic syndromes and studied most intensively in Marfan syndrome, a disease associated with tall stature, muscle weakness, lens dislocation, heart valve deformities and aortic aneurism. Although originally thought to arise from fragmentation of elastin fibers resulting from lack of fibrillin expression or incorporation into microfibrils, analysis of mouse models hypomorphic for fibrillin have shown that Marfan pathology is associated with elevated TGFβ signaling and can be ameliorated by administration of TGFβ antagonists [43, 99] . In Marfan syndrome, excessive TGFβ activation is proposed to result from insufficient sites within the ECM to sequester and quench TGFβ [43] . In contrast mutations in the integrin-binding RGD domain of fibrillin-1 that impair association with integrins αvβ3 and αvβ6 produce Stiff Skin Syndrome characterized by enhanced fibrillin 1, elastin and LTBP4 deposition. In this syndrome, excess TGFβ signaling is thought to arise due to latent TGFβ production exceeding the available sites on the ECM [60] .
LTBPs in Mammary Development
Surprisingly, given their central function in controlling the bioavailability of a regulator of breast development and homeostasis, the role of LTBPs in the mammary gland is largely unstudied. Ltbp1L has been studied in the mammary gland by using a knock in mouse (Ltbp1 +/lZ ) where lacZ has been inserted downstream of the Ltbp1L promoter. Analysis of this reporter mouse reveals that Ltbp1L-LacZ is expressed in a dynamic spatio-temporal pattern throughout mammary development as summarized in Fig. 3 b During puberty, LTBP1L-LacZ is expressed in quiescent ductal luminal cells but not in the terminal end buds. c During pregnancy, LTBP1L-LacZ expression is high in the luminal cells of ducts and side branches, but is absent from secretory structures such as alveoli. d LTBP1L-LacZ is not expressed during lactation, but is seen in a subset of cells during involution Hiremath and Cowin unpublished results). Ltbp1L-LacZ becomes strongly expressed in the embryonic mammary region around E12.5. At this stage it is found exclusively within the condensing mammary mesenchyme surrounding the epithelial buds. Robust mesenchymal expression continues under the developing nipple throughout embryonic development. Postnatally, the reporter expression continues in stromal cells underneath the nipple shield and becomes most intensely expressed in smooth muscle at the nipple base. In addition to this mesenchymal expression, Ltbp1L-LacZ appears within lumenal epithelia, coinciding spatially and temporally with the onset of lumen formation at E17.5. During puberty, Ltbp1L-LacZ expression is found exclusively throughout the luminal epithelial layer of the developing ductal system. However, it is notably absent from the cap and body cells of the terminal end buds, which are multilayered foci of active proliferation that provide the powerhouse for ductal extension. Within these structures, Ltbp1L-LacZ is restricted to a few body cells immediately facing the luminal cavity. Luminal epithelial expression of Ltbp1L-LacZ continues within the permanent ductal system and appears within all of the developing side-branches but is notably absent from both the developing and differentiated alveoli during pregnancy. During lactation Ltbp1L-LacZ disappears altogether but becomes robustly expressed within 24 h of pup weaning. It is strongly expressed coincident with the wave of alveolar apoptosis that occurs during the earliest stage of involution and becomes restricted again to the luminal cells of the permanent ductal tree at later stages.
These data show that a single Ltbp gene is active in a very specific and dynamic manner during mammary development. The pattern of Ltbp1L-lacZ expression suggests that Ltbp1L and any associated TGFβ is positioned to contribute towards embryonic mammary mesenchyme signaling. There are no published reports of TGFβ expression during embryonic mammary development. However, TGFβ1 and 3 mRNAs have been detected in the mammary mesenchyme in microarrays of microdissected mammary buds and thus represent potential partners (Beatrice Howard personal communication). These same analyses have revealed TGFβ receptors in both epithelial and mesenchymal compartments. Thus, Ltbp1 may present TGFβ for autocrine signaling during the process of mammary mesenchyme condensation. This event phenotypically resembles some aspects of fibrosis, a matrixbuilding process that is promoted by TGFβ activity [16] . Alternatively, Ltbp1 may be presenting TGFβ for paracrine signaling to the mammary bud and later to the overlying developing nipple. Adult nipples are sites of considerable elastin synthesis and undergo extensive matrix remodeling during the course of each pregnancy. Elastin and many other genes, which encode ECM proteases are known targets of TGFβ signaling. The coincidence of Ltbp1L-LacZ expression in ducts with lumen formation suggests possible roles in polarity and lumenal cavitation, as well as in maintaining the general growth restraint and quiescence of luminal cells lining the mammary ducts. The dramatic surge in expression during early stages of involution exactly mirrors that of TGFβ3 elevation and indicates potential roles in promoting apoptosis [9] . Preliminary data show Ltbp1 is deposited around luminal cells as well as in the underlying periductal stroma. Thus, Ltbp1 is positioned to affect luminal, myoepithelial and stromal populations. Given that Ltbp and TGFβ must be synthesized within the same cell in order to form a large latent complex, the pattern of Ltbp1L-LacZ expression points to TGFβ3 as the most likely partner. All four Ltbp mRNAs can be detected in the mammary gland. Important questions remain concerning their specific sites of expression and deposition and how these contribute to regulating synthesis of the periductal ECM and TGFβ bioavailability within what has been termed this instructive platform [43] .
LTBPs are Increased and Decreased in Breast Cancers and Cell Lines
Currently, a systematic analysis on breast tissue and breast cancer cell lines is needed. Although sparse, the literature nevertheless shows that both loss and gain of LTBP expression is found in breast cancers (see Table 1 ). This biphasic effect mirrors that of TGFβ in breast cancer and underscores the importance of maintaining physiological levels of LTBP expression for homeostasis of the normal mammary gland. Three publications have reported significant changes in LTBP expression in breast cancers. In one, LTBP4 mRNA expression was downregulated in five human mammary adenocarcinomas when compared with matched healthy mammary tissues from the same patient. Intriguingly, a drop in TGFβ1 expression and deposition and a compensatory increase in TGFβ2 accompanied reduction in LTBP4 [100] . Two further studies of canine breast tumors also showed a significant drop in LTBP4 protein expression when compared to normal breast tissue. In one, LTBP4 mRNA expression decreased in a graded manner during tumor progression with a concomitant increase in LTBP1 mRNA [101, 102] . LTBP4 was one of only three genes within a forty-nine gene signature that accurately distinguished benign from malignant tumors [101] . In silico analysis of expression profiling data available on the Oncomine database reveals three further reports where LTBP cDNAs were included in gene expression profiles from breast cancer tissues and compared to normal breast tissues (see Table 1 ). Collectively, these data show that LTBP isoform expression relative to one another is dysregulated in breast cancer and suggest that further study is warranted on larger cohorts.
A similar situation was found in human breast cancer cell lines (see Table 1 ). MCF7 and HS578T breast carcinoma cell lines show lower LTBP4 mRNA and protein levels compared to a non-transformed variant cell line, Hs578Bst. Oncomine analyses show that all four LTBPs are expressed to variable degrees in a wide range of breast cell lines (see Table 1 ). Consistent with the observations in human breast tumors, LTBP4 was absent from most breast cancer cell lines and in general LTBP1 expres< sion appears inversely related to that of LTBP2 and 3 [103] [104] [105] .
Two studies provide evidence that increasing LTBP1 may promote metastasis. Massague and colleagues set out to identify tissue-specific metastatic signatures within primary breast cancers that could predict the propensity to metastasize to brain or to lungs. To do this they took sublines of metastatic MDA-MB-231 cells, injected them into immunocompromised mice. After several rounds of in vivo selection for tissue-specific metastasis they compared the gene profiles of the aggressively metastatic subclones displaying specific tropism to that of parental cells. Microarray profiling revealed 18 gene and 17 gene signatures that could stratify patients who were at high risk for developing lung or brain metastasis respectively. These signatures were clinically relevant and identified patients with significantly worse outcome. Importantly, LTBP1 was one of only six genes that were common to both of these metastasis signatures. Thus LTBP1 elevation appears to play a fundamental role in enhancing metastatic behavior [106] [107] [108] .
How might both loss and gain of LTBP1 be linked to breast cancer? First, this feature is highly reminiscent of the between the cell surface and fibrillins. The integrin-LLC association with fibronectin and fibrillins provide extra footholds between the cell and the matrix. Different matrix molecules assemble distinct complements and arrangements of integrins. In the case of fibronectin it is hypothesized that stretch mediated integrin activation of TGFβ will stimulate the EMT transcriptional program to reinforce migratory behavior biphasic effects of TGFβ on breast cancer and is likely linked to LTBPs role in TGFβ biology. As LTBP1 is required for efficient secretion of TGFβ, then decreased LTBP1 expression is predicted to significantly reduce the amount of latent TGFβ emerging from cells. This in turn would critically reduce the pool of extracellular latent TGFβ available for activation, thereby limiting growth restraining signals and unleashing cell proliferation.
In contrast, elevating LTBP1 could produce one of three effects. First, it is predicted to lead to full LLC occupancy of the available ECM binding sites. Second, increasing LTBP1 could result in secretion of free LTBP (without its TGFβ partner) a scenario predicted to lead to competitive occupancy of ECM binding sites and displacement of LLC complexes. Both of these events would cause the gland to become pathologically awash in untethered LLC that is highly susceptible to protease activation. This scenario, described as "an overflowing sink", is akin to mechanisms proposed to account for excessive TGFβ activation in stiff skin syndrome associated with fibrillin mutations [60] . A third potential scenario (see Figs. 1c and 4a) is that increased LTBP1 will lead to LLC occupying not only all of the usual mature microfibrillar binding sites but also becoming backlogged and entrenched on what would, under normal conditions, be transient sites on fibronectin. A necessary corollary of this model is that aberrant longterm occupancy of fibronectin may provide a motogenic signal to the cell.
It has been hypothesized that cells respond not to individual signals from growth factors acting in isolation but rather to combinations of signals that are dictated by the context of particular matrices [109] . This theory posits that different elements of the ECM, by virtue of their unique protein domain arrangements, bring specific complements of receptors into cis alignment such that "cells hear chords and not single notes" [109] . Fibronectin has long been associated with events involving cell migration and metastasis and it is both the initial binding partner for LTBP1 and a TGFβ target gene [110] . Thus, the integrin-LLC bridge provides the cell with extra footholds on fibronectin and simultaneously generates the stretchmediated TGFβ signals that will reinforce migratory behavior by inducing transcription of fibronectin as part of the EMT program. In breast cancer cell lines expressing elevated LTBP1, we speculate that fibronectin and LTBP1 engage in a fatal pas de deux that, to take the musical analogy further, strikes the chord for metastatic migration.
Conclusions
In conclusion, LTBPs regulate the secretion, localization, presentation and activation of their specific latent TGFβ partners. As binding sites for LTBPs within the ECM are finite homeostasis depends upon the delivery of critical concentrations of LLC. Diminished occupancy likely results in insufficient TGFβ leading to unbridled cell proliferation, whereas excess occupancy is likely to enhance metastatic properties by promoting TGFβ-induced EMT. Little is currently understood about the role of individual LTBPs in the mammary gland. The importance of further studies on this topic is warranted by their important functions in regulating TGFβ-a major breast tumor suppressor and oncogene-and by their appearance in multiple gene signatures predictive of enhanced metastatic behavior.
